Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study
Martin Hutchings(University of Copenhagen), Pieternella J. Lugtenburg(Erasmus MC Cancer Institute), Martine E.D. Chamuleau(Dutch Cancer Society), Kim Linton(The Christie NHS Foundation Trust), Rogier Mous(University Medical Center Utrecht), Dena DeMarco(Genmab (United States)), Kuo-mei Chen(Genmab (United States)), David Cunningham(Royal Marsden NHS Foundation Trust), Christopher Chiu(Genmab (United States)), Ada Azaryan(Genmab (United States)), Roberto S Oliveri(Genmab (Denmark)), Brian Elliott(Genmab (United States)), Tahamtan Ahmadi(Genmab (United States)), David Lewis(University Hospitals Plymouth NHS Trust), Michael Roost Clausen(Vejle Sygehus), Tommy Li(Genmab (United States)), Peter Johnson(University of California, San Francisco)
Cited by 337
Related Papers
Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
|New England Journal of Medicine|2008|2.3k
Adjuvant Chemotherapy With Fluorouracil Plus Folinic Acid vs Gemcitabine Following Pancreatic Cancer Resection
|JAMA|2010|1.4k
Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study
|The Lancet Oncology|2019|1.2k
Oesophageal cancer
|Nature Reviews Disease Primers|2017|1.1k